Soleno Therapeutics (SLNO) Non-Current Deferred Tax Liability (2017 - 2023)
Soleno Therapeutics (SLNO) posted quarterly Non-Current Deferred Tax Liability of $1.8 million for Q4 2023, up 14.81% quarter-over-quarter from $1.6 million in Q4 2018.
Soleno Therapeutics (SLNO) Non-Current Deferred Tax Liability (2017 - 2023) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $1.8 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.8 million; the TTM figure through Dec 2023 stood at $1.8 million (changed N/A YoY), while the FY2023 annual figure was $1.8 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability grew to $1.8 million in Q4 2023 per SLNO's latest filing, from $1.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.8 million in Q4 2023 and bottomed at $1.8 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.84 Mn |
| Dec 31, 2023 | 1.84 Mn |
| Dec 31, 2018 | 1.60 Mn |
| Dec 31, 2018 | 1.60 Mn |
| Dec 31, 2017 | 1.60 Mn |
| Dec 31, 2017 | 1.60 Mn |